AGP Executive Report
Last update: 4 hours agoChikungunya Vaccine: UK regulators have withdrawn authorization for Valneva’s IXCHIQ after reviewing existing safety data; the company says no new safety issue was identified. The decision applies only to the UK, with approvals in the EU, Canada, Brazil and other markets unchanged. Valneva will not appeal.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.